GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Price-to-Owner-Earnings

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Price-to-Owner-Earnings : (As of May. 26, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Price-to-Owner-Earnings?

As of today (2024-05-26), CERo Therapeutics Holdings's share price is $0.9178. CERo Therapeutics Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CERo Therapeutics Holdings's Price-to-Owner-Earnings or its related term are showing as below:


CERO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-26), CERo Therapeutics Holdings's share price is $0.9178. CERo Therapeutics Holdings does not have enough years/quarters to calculate the Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022. Therefore GuruFocus does not calculate PE Ratio at this moment.

As of today (2024-05-26), CERo Therapeutics Holdings's share price is $0.9178. CERo Therapeutics Holdings does not have enough years/quarters to calculate the EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022. Therefore GuruFocus does not calculate PE Ratio without NRI at this moment.


CERo Therapeutics Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for CERo Therapeutics Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Price-to-Owner-Earnings Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Price-to-Owner-Earnings
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Price-to-Owner-Earnings - -

Competitive Comparison of CERo Therapeutics Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, CERo Therapeutics Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Price-to-Owner-Earnings falls into.



CERo Therapeutics Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CERo Therapeutics Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.9178/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CERo Therapeutics Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines